MYmAb Biologics
Research & Development
Beating Cancer Through Dedication & Determination
At MYmAb Biologics, our experienced researchers are committed to advancing research and development, with the goal of facilitating cancer research as a whole and improving quality of life. Every research we undertake adheres to rigorous standards, ensuring the integrity and dependability of our research findings.
Research Team
Ms. Christina Tiong Sing Yee
Miss Christina is a passionate research assistant in MYmAb Biologics. Graduating with a Bachelor’s degree in biotechnology from Universiti Putra Malaysia, Miss Christina brings a wealth of knowledge in driving progress in antibody research with biotechnological advancements.
Research Team
Ms. Ooi Yi Lin
Miss Ooi is a dedicated research assistant in our translational research department. She holds a Bachelor’s degree in Biotechnology from Universiti Putra Malaysia. With her knowledge and laboratory skills, Miss Ooi plays a role in enhancing the production of effective therapeutic antibodies.
GlykoGuard Antibody Technology Platform
Glycans are chain structures that are composed of monosaccharides linked together by chemical bonds. Glycan structures are represented in a schematic diagram in which every type of monosaccharides is represented with a different color.
In tumour tissue, the occurrence of aberrant glycosylation leads to the overexpression of tumour-associated glycans. Many of these aberrantly expressed tumour-associated glycans have been shown to correlate with the poor prognosis and survival of cancer patients. Hence, they are a class of attractive antigens for the development of anti-cancer immunotherapy. However, due to their low immunogenicity, glycans have been proven to be difficult to induce a high-affinity IgG antibody response. In addition, their complex structures often induce non-specific antibody responses.
At MYmAb Biologics, we leverage an experienced scientific team to develop a new antibody technology platform, called GlykoGuard. We are a group of committed scientists aims to generate highly specific, high-affinity IgG anti-glycan monoclonal antibodies to a broad range of tumour associated glycan antigens overexpressed in tumour tissues. We are excited about the potential of GlykoGuard to generate high-quality anti-glycan monoclonal antibodies that can be used in therapy, diagnosis and research. What drives us all at MYmAb Biologics is the desire to improve patients’ health and to help patients live longer.
Our Publications
Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination
The emergence of SARS-CoV-2 variants raises concerns of reduced COVID-19 vaccine efficacy. Our study suggests that vaccines that induce broader sterilizing immunity are essential to fight against fast-emerging variants.
Blogs & News
Learn more about our latest blogs and news here!
Cancer Statistics in Southeast Asian Countries: Gender, Types, and More Cancer remains one of the most significant public health challenges worldwide, and …
How Tissue Microarrays (TMA) Contribute to Translational Research: Bridging the Gap Between Lab and Clinic What is Translational Research? In today’s rapidly …
Digital Pathology – An Advanced Way to Preserve Your Research Outcome In today’s rapidly evolving world of medical and scientific research, digital …
MYmAb Biologics Receives RM 1.3 Million GVPD Grant for Tissue Microarray Development August 2024: We are excited to announce that MYmAb Biologics …